Abstract: Objective: To discuss the efficacy and safety of hepatitis B immunoglobulin(HBIG) in blocking the hepatitis B virus(HBV) transmission in mother-to-infant.Methods: One hundred and ten HBV puerperal carriers were divided into the observation group and control group on voluntary basis(55 cases each group).The observation group were injected with HBIG at 28 gestational weeks,and the control group did not be injected.The detection rates of hepatitis B surface antigen(HBsAg) in newborns and hepatitis B surface antibody(HBsAb) in newborns after 6-month treatment between two groups were compared.Results: The detection rates of newborns HBsAg in observation group and control group were 9.09% and 34.55%,respectively,the difference of which was statistical significance(P<0.01).The detection rate of HBsAb in newborns after 6-month treatment(64.55%) was significantly better than that in 1-month newborns(22.72%)(P<0.01),and there were not significant adverse reactions in pregnant woman and newborn.Conclusions: HBIG in blocking the HBV transmission in mother-to-infant is effective and safe,which can be applied in clinic.